A new approach is needed to de-risk the drug development process, given that the probability of successfully advancing a new product from phase 1 trials through regulatory approval is a mere 10.5%.
Adopting a “fail fast” strategy can help companies future-proof clinical trials by identifying potential roadblocks early enough in a program that they can be mitigated before they obstruct the path to market.
This report offers some steps life science companies can take to de-risk their clinical trials and improve their odds of market approval. Among these are:
- Market selection
- Regulatory engagement
- Participant recruitment and retention
- Treatment preferences
- Protocol flexibility
Download the report to access detailed insights.